These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 21397729)

  • 41. Multidisciplinary managed care networks-Life-saving interventions for hepatitis C patients.
    Tait JM; Wang H; Stephens BP; Miller M; McIntyre PG; Cleary S; Dillon JF
    J Viral Hepat; 2017 Mar; 24(3):207-215. PubMed ID: 28127941
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 Study.
    Tsui JI; Currie S; Shen H; Bini EJ; Brau N; Wright TL;
    Dig Dis Sci; 2008 Mar; 53(3):809-14. PubMed ID: 17823868
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outcomes of a Pharmacist-Led Hepatitis C Virus Treatment Program in an Urban Safety-Net Health System, Chicago, 2017-2019.
    Hunt BR; Cetrone H; Sam S; Glick NR
    Public Health Rep; 2022; 137(4):702-710. PubMed ID: 34043923
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Virus C cure as a motivation for strong lifestyle change?
    Couzigou P
    Clin Gastroenterol Hepatol; 2012 Mar; 10(3):326; author reply 326-7. PubMed ID: 21982966
    [No Abstract]   [Full Text] [Related]  

  • 45. Characteristics and impact of methamphetamine use in patients with chronic hepatitis C.
    Riley DE; Liu L; Cohen B; Robinson S; Groessl EJ; Ho SB
    J Addict Med; 2014; 8(1):25-32. PubMed ID: 24343127
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatitis C viral dynamics: basic concept and clinical significance.
    Jessner W; Watkins-Riedel T; Formann E; Steindl-Munda P; Ferenci P
    J Clin Virol; 2002 Dec; 25 Suppl 3():S31-9. PubMed ID: 12467775
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Liver-specific case fatality due to chronic hepatitis C virus infection: a systematic review.
    Szabo SM; Samp JC; Walker DR; Lane S; Cline SK; Gooch KL; Jimenez-Mendez R; Levy AR
    Ann Hepatol; 2015; 14(5):618-30. PubMed ID: 26256890
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HCV genotypes distribution pattern in India.
    Bokharaei-Salim F; Alavian SM
    Indian J Med Res; 2012 Aug; 136(2):306-7; author reply 307-8. PubMed ID: 22960903
    [No Abstract]   [Full Text] [Related]  

  • 49. Project ECHO Revisited: Propensity Score Analysis And HCV Treatment Outcomes.
    Page K; Qeadan F; Qualls C; Thornton K; Arora S
    Hepat Med; 2019; 11():149-152. PubMed ID: 31632162
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Why 88% of US military veterans with HCV are not treated.
    Cecil B
    J Hepatol; 2012 Oct; 57(4):924. PubMed ID: 22510264
    [No Abstract]   [Full Text] [Related]  

  • 51. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.
    van der Meer AJ; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Heathcote EJ; Manns MP; Kuske L; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
    JAMA; 2012 Dec; 308(24):2584-93. PubMed ID: 23268517
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response.
    Simmons B; Saleem J; Heath K; Cooke GS; Hill A
    Clin Infect Dis; 2015 Sep; 61(5):730-40. PubMed ID: 25987643
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
    Poordad F; Hezode C; Trinh R; Kowdley KV; Zeuzem S; Agarwal K; Shiffman ML; Wedemeyer H; Berg T; Yoshida EM; Forns X; Lovell SS; Da Silva-Tillmann B; Collins CA; Campbell AL; Podsadecki T; Bernstein B
    N Engl J Med; 2014 May; 370(21):1973-82. PubMed ID: 24725237
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.
    Lawitz E; Poordad F; Brainard DM; Hyland RH; An D; Dvory-Sobol H; Symonds WT; McHutchison JG; Membreno FE
    Hepatology; 2015 Mar; 61(3):769-75. PubMed ID: 25322962
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden.
    Younossi Z; Park H; Henry L; Adeyemi A; Stepanova M
    Gastroenterology; 2016 Jun; 150(7):1599-1608. PubMed ID: 26924097
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
    Pearlman BL; Ehleben C; Perrys M
    Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
    Zeuzem S; Jacobson IM; Baykal T; Marinho RT; Poordad F; Bourlière M; Sulkowski MS; Wedemeyer H; Tam E; Desmond P; Jensen DM; Di Bisceglie AM; Varunok P; Hassanein T; Xiong J; Pilot-Matias T; DaSilva-Tillmann B; Larsen L; Podsadecki T; Bernstein B
    N Engl J Med; 2014 Apr; 370(17):1604-14. PubMed ID: 24720679
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies.
    Morgan RL; Baack B; Smith BD; Yartel A; Pitasi M; Falck-Ytter Y
    Ann Intern Med; 2013 Mar; 158(5 Pt 1):329-37. PubMed ID: 23460056
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C.
    Ponziani FR; Mangiola F; Binda C; Zocco MA; Siciliano M; Grieco A; Rapaccini GL; Pompili M; Gasbarrini A
    World J Hepatol; 2017 Mar; 9(7):352-367. PubMed ID: 28321272
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients.
    Backus LI; Belperio PS; Shahoumian TA; Loomis TP; Mole LA
    Hepatology; 2016 Aug; 64(2):405-14. PubMed ID: 27115523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.